Sellers E M, Hoornweg K, Busto U E, Romach M K
Department of Pharmacology, Faculty of Pharmacy, University of Toronto, Ontario.
Can J Clin Pharmacol. 1999 Spring;6(1):18-25.
Concern has been raised that the barbiturate component of barbiturate-containing analgesics constitutes a public and individual health problem because of information from literature before 1966 concerning preclinical and clinical abuse liability, and the dependence risk of barbiturates. The safety of barbiturates alone and in combination in analgesics was reviewed. In addition, information from manufacturers of combination products were evaluated. A meta-analysis was not possible because of the paucity of formal clinical trials. Even though barbiturates have a narrow margin of safety and substantial abuse potential, there is no evidence that barbiturate-containing analgesics without codeine represent a public health or social problem because of their abuse potential. However, proper studies to confirm this theory have not been performed. In the absence of better data concerning efficacy and lack of dependence potential, barbiturate-containing analgesics are not first-line medications for the initiation of treatment for pain. Codeine-containing combination analgesics have the potential to be a more important public health problem than those with only barbiturate in the combination.
由于1966年以前文献中有关巴比妥类药物临床前和临床滥用倾向以及巴比妥类药物成瘾风险的信息,含巴比妥类的镇痛药中的巴比妥成分被认为构成了一个公共和个人健康问题。对巴比妥类药物单独使用以及与镇痛药联合使用时的安全性进行了综述。此外,还评估了复方产品制造商提供的信息。由于正式临床试验数量不足,无法进行荟萃分析。尽管巴比妥类药物的安全范围窄且有很大的滥用可能性,但没有证据表明不含可待因的含巴比妥类镇痛药因其滥用可能性而构成公共卫生或社会问题。然而,尚未进行适当的研究来证实这一理论。在缺乏关于疗效和无成瘾可能性的更好数据的情况下,含巴比妥类镇痛药并非疼痛治疗起始阶段的一线用药。含可待因的复方镇痛药可能比仅含巴比妥类的复方镇痛药构成更重要的公共卫生问题。